Source: FinanzNachrichten

LumiThera: LumiThera Inc.: LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data

LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, multi-center clinical ...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Clark E. Tedford's photo - President & CEO of LumiThera

President & CEO

Clark E. Tedford

CEO Approval Rating

90/100

Read more